Ligand Efficiency Indices for Drug Discovery

Ligand Efficiency Indices for Drug Discovery

Volumn , Issue , 2013, Pages

  Abad Zapatero, Celerino ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013794803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2012-0-02270-3     Document Type: Book

References (141)

1. Berman H.M. The Protein Data Bank: a historical perspective. Acta crystallographica Section A, Foundations of crystallography 2008, 64(Pt 1):88-95.
2. Irwin J.J., Shoichet B.K. ZINC-a free database of commercially available compounds for virtual screening. Journal of chemical information and modeling 2005, 45(1):177-182.
3. Bairoch A., Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic acids research 2000, 28(1):45-48.
4. Kramer C., Kalliokoski T., Gedeck P., Vulpetti A. The experimental uncertainty of heterogeneous public K(i) data. Journal of medicinal chemistry 2012, 55(11):5165-5173.
5. Southan C., Varkonyi P., Muresan S. Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds. Journal of cheminformatics 2009, 1(1):10.
6. Bellis L.J., Akhtar R., Al-Lazikani B., Atkinson F., Bento A.P., Chambers J., et al. Collation and data-mining of literature bioactivity data for drug discovery. Biochemical society transactions 2011, 39(5):1365-1370.
7. Degtyarenko K., de Matos P., Ennis M., Hastings J., Zbinden M., McNaught A., et al. ChEBI: a database and ontology for chemical entities of biological interest. Nucleic acids research 2008, 36(Database issue):D344-D350.
8. Abad-Zapatero C. Notes of a protein crystallographer: on the high-resolution structure of the PDB growth rate. Acta crystallographica Section D, Biological crystallography 2012, 68(Pt 5):613-617.
9. Berman H., Henrick K., Nakamura H. Announcing the worldwide Protein Data Bank. Nature structural biology 2003, 10(12):980.
10. Lawson C.L., Baker M.L., Best C., Bi C., Dougherty M., Feng P., et al. EMDataBank.org: unified data resource for CryoEM. Nucleic acids research 2011, 39(Database issue):D456-D464.
11. Wang R., Fang X., Lu Y., Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. Journal of medicinal chemistry 2004, 47(12):2977-2980.
12. Hu L., Benson M.L., Smith R.D., Lerner M.G., Carlson H.A. Binding MOAD (Mother Of All Databases). Proteins 2005, 60(3):333-340.
13. Gaulton A., Bellis L.J., Bento A.P., Chambers J., Davies M., Hersey A., et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic acids research 2012, 40(Database issue):D1100-D1107.
14. Olah M, Rad R, Ostopovici L, Bora A, Hadaruga N, Hadaruga D, et al. WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery. Chemical Biology: From Small Molecules to Systems Biology and Drug Design 2007, Wiley-VCH Verlag CmbH & Co., Weinheim. S.L. Schreiber, T. Kapoor, G. Wess (Eds.).
15. Weininger D. SMILES 1: Introduction and encoding rules. Journal of chemical information and computer science 1988, 28:31-36.
16. Weininger D., Weininger A., Weininger J.L. SMILES 2. Algorithm for generation of unique SMILES notation. Journal of chemical information and computer science 1989, 29:97-191.
17. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubiliy and permeability in drug discovery and development settings. Advances drug delivery reviews 1997, 23:3-25.
18. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug discovery today 2004, 9(May):430-431.
19. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic acids research 2006, 34(Database issue):D668-D672.
20. Chen X., Liu M., Gilson M.K. BindingDB: a web-accessible molecular recognition database. Combinatorial chemistry and high throughput screening 2001, 4(8):719-725.
21. Chen X., Lin Y., Gilson M.K. The binding database: overview and user's guide. Biopolymers 2001, 61(2):127-141.
22. Chen X., Lin Y., Liu M., Gilson M.K. The binding database: data management and interface design. Bioinformatics 2002, 18(1):130-139.
23. Bolton EE., Wang Y., Thiessen PA, Bryant SH. PubChem: Integrated Platform of Small Molecules and Biological Activities. Annual Reports in Computational Chemistry 2008, 4:217-241.
24. Li Q., Cheng T., Wang Y., Bryant S.H. PubChem as a public resource for drug discovery. Drug discovery today 2010, 15(23-24):1052-1057.
25. Nicola G., Liu T., Gilson M.K. Public domain databases for medicinal chemistry. Journal of medicinal chemistry 2012, 55(16):6987-7002.
26. Abad-Zapatero C. A sorcerer's apprentice and the Rule of Five: from rule of thumb to commandments and beyond. Drug discovery today 2007, 12(23-24):995-997.
27. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., et al. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic acids research 2011, 39(Database issue):D1035-D1041.
28. Liu T., Lin Y., Wen X., Jorissen R.N., Gilson M.K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic acids research 2007, 35(Database issue):D198-D201.
29. Andrews P.R., Craik D.J., Martin J.L. Functional group contributions to drug-receptor interactions. Journal of medicinal chemistry 1984, 27(12):1648-1657.
30. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proceedings of the national academy of sciences of the United States of America 1999, 96(18):9997-10002.
31. Pelphrey P.M., Popov V.M., Joska T.M., Beierlein J.M., Bolstad E.S., Fillingham Y.A., et al. Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. Journal of medicinal chemistry 2007, 50(5):940-950.
32. Saxty G., Woodhead S.J., Berdini V., Davies T.G., Verdonk M.L., Wyatt P.G., et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. Journal of medicinal chemistry 2007, 50(10):2293-2296.
33. Ligand efficiency poll results. 2011. Available from: <>. http://practicalfragments.blogspot.com/2011/08/ligand-efficiency-metrics-poll-results.html.
34. Freire E. Do enthalpy and entropy distinguish first in class from best in class?. Drug discovery today 2008, 13(19-20):869-874.
35. Freire E. A thermodynamic approach to the affinity optimization of drug candidates. Chemical biology and drug design 2009, 74(5):468-472.
36. Ferenczy G.G., Keseru G.M. Enthalpic efficiency of ligand binding. Journal of chemical information and modeling 2010, 50(9):1536-1541.
37. Reynolds C.H., Holloway K.M. Thermodynamics of ligand binding and efficiency. ACS medicinal chemistry letters 2011, 2:433-437.
38. Garcia-Sosa A.T., Hetenyi C., Maran U. Drug efficiency indices for improvement of molecular docking scoring functions. Journal of computational chemistry 2009, 31(1):174-184.
39. Verdonk M.L., Rees D.C. Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem 2008, 3(8):1179-1180.
40. Abad-Zapatero C., Metz J.M. Ligand efficiency indices as guideposts for drug discovery. Drug discovery today 2005, 10(7):464-469.
41. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. Expert opinion in drug discovery 2007, 2(4):469-488.
42. Abad-Zapatero C., Perisic O., Wass J., Bento P.A., Overington J., Al-Asikani B., et al. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug discovery today 2010, 15(19-20):804-811.
43. Gracias V., Ji Z., Akritopoulou-Zanze I., Abad-Zapatero C., Huth J.R., Song D., et al. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorganic and medicinal chemistry letters 2008, 18(8):2691-2695.
44. Lepifre F., Christmann-Franck S., Roche D., Leriche C., Carniato D., Charon C., et al. Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold. Bioorganic and medicinal chemistry letters 2009, 19(13):3682-3685.
45. Roche D., Carniato D., Leriche C., Lepifre F., Christmann-Franck S., Graedler U., et al. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I. Bioorganic and medicinal chemistry letters 2009, 19(10):2674-2678.
46. Hajduk P.J. Fragment-based drug design: how big is too big?. Journal of medical chemistry 2006, 49:6972-6976.
47. Tanaka D., Tsuda Y., Shiyama T., Nishimura T., Chiyo N., Tominaga Y., et al. A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. Journal of medicinal chemistry 2011, 54(3):851-857.
48. Abad-Zapatero C., Perisic O., Wass J., Bento A.P., Overington J., Al-Lazikani B., et al. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug discovery today 2010, 15(19-20):804-811.
49. Abad-Zapatero C., Blasi D. Ligand efficiency indices (LEIs): more than a simple efficiency yardstick. Molecular informatics 2011, 30(2-3):122-132.
50. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. Journal of pharmacological and toxicological methods 2000, 44(1):235-249.
51. Reynolds C.H., Tounge B.A., Bembenek S.D. Ligand binding efficiency: trends, physical basis, and implications. Journal of medicinal chemistry 2008, 51(8):2432-2438.
52. Willem J., Nissink J.W. Simple size-independent measure of ligand efficiency. Journal of chemical information and modeling 2009, 49(6):1617-1622.
53. Orita M., Ohno K., Niimi T. Two "Golden Ratio" indices in fragment-based drug discovery. Drug discovery today 2009, 14(5-6):321-328.
54. Leeson P.D., Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature reviews drug discovery 2007, 6(11):881-890.
55. Mortenson P.N., Murray C.W. Assessing the lipophilicity of fragments and early hits. Journal of computer-aided molecular design 2011, 25(7):663-667.
56. Keseru G.M., Makara G.M. The influence of lead discovery strategies on the properties of drug candidates. Nature reviews Drug discovery 2009, 8(3):203-212.
57. Ladbury J.E., Klebe G., Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nature reviews drug discovery 2010, 9(1):23-27.
58. Wager T.T., Hou X., Verhoest P.R., Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS chemical neuroscience 2010, 1(6):435-449.
59. Braggio S., Montanari D., Rossi T., Ratti E. Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert opinion on drug discovery 2010, 5(7):609-618.
60. Bickerton G.R., Paolini G.V., Besnard J., Muresan S., Hopkins A.L. Quantifying the chemical beauty of drugs. Nature chemistry 2012, 4(2):90-98.
61. Hann M.M., Keseru G.M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nature reviews drug discovery 2012, 11(5):355-365.
62. Lipinski C., Hopkins A. Navigating chemical space for biology and medicine. Nature 2004, 432:855-861.
63. Oprea T.I., Gottfries J. Chemography: the art of navigating in chemical space. Journal of combinatorial chemistry 2001, 3(2):157-166.
64. Bajorath J. Modeling of activity landscapes for drug discovery. Expert opinion on drug discovery 2012, 7(6):463-473.
65. Bajorath J., Peltason L., Wawer M., Guha R., Lajiness M.S., Van Drie J.H. Navigating structure-activity landscapes. Drug discovery today 2009, 14(13-14):698-705.
66. Bon R.S., Waldmann H. Bioactivity-guided navigation of chemical space. Accounts of chemical research 2010, 43(8):1103-1114.
67. Cortes-Cabrera A, Morreale A, Gago F, Abad-Zapatero C. AtlasCBS: a web server to map and explore chemico-biological space. Journal of computer-aided molecular design 2012, 26(9):995-1003.
68. Hajduk P.J. Fragment-based drug design: how big is too big?. Journal of medicinal chemistry 2006, 49(24):6972-6976.
69. Abad-Zapatero C. Ligand Efficiency Indices for effective drug discovery. Expert opinion in drug discovery 2007, 2(4):469-488.
70. Abad-Zapatero C., Perisic O., Wass J., Bento A.P., Overington J., Al-Lazikani B., et al. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug discovery today 2010, 15(19-20):804-811.
71. Lepifre F., Christmann-Franck S., Roche D., Leriche C., Carniato D., Charon C., et al. Discovery and structure-guided drug design of inhibitors of 11β-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold. Bioorganic and medicinal chemistry letters 2009, 19(13):3682-3685.
72. Roche D., Carniato D., Leriche C., Lepifre F., Christmann-Franck S., Graedler U., et al. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorganic and medicinal chemistry letters 2009, 19(10):2674-2678.
73. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubiliy and permeability in drug discovery and development settings. Advanced drug delivery reviews 1997, 23:3-25.
74. Ertl P., Rohde B., Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. Journal of medicinal chemistry 2000, 43(20):3714-3717.
75. Cruciani G., Pastor M., Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. European journal of pharmaceutical sciences: official journal of the European federation for pharmaceutical sciences 2000, 11(Suppl 2):S29-S39.
76. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry 2002, 45(12):2615-2623.
77. Congreve M., Carr R., Murray C., Jhoti H. A "rule of three" for fragment-based lead discovery?. Drug discovery today 2003, 8:876-877.
78. Kubinyi H. Drug research: myths, hype and reality. Nature reviews drug discovery 2003, 2(8):665-668.
79. Wenlock M.C., Austin R.P., Barton P., Davis A.M., Leeson P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. Journal of medicinal chemistry 2003, 46(7):1250-1256.
80. Abad-Zapatero C. A Sorcerer's apprentice and the Rule of Five: from rule of thumb to commandments and beyond. Drug discovery today 2007, 12(23/24):995-997.
81. Zhang M.-Q., Wilkinson B. Drug discovery beyond the "rule-of-five". Current opinion in biotechnology 2007, 18(6):478-488.
82. Sepkowitz K.A. One hundred years of Salvarsan. The New England journal of Medicine 2011, 365(4):291-293.
83. Abad-Zapatero C., Blasi D. Ligand efficiency indices (LEIs): more than a simple efficiency yardstick. Molecular informatics 2011, 30(2-3):122-132.
84. Lachance H., Wetzel S., Kumar K., Waldman H. Charting, navigating, and populating natural product chemical space for drug discovery. Journal of medicinal chemistry 2012, 55(13):5989-6001.
85. Bon R.S., Waldmann H. Bioactivity-guided navigation of chemical space. Accounts of chemical research 2010, 43(8):1103-1114.
86. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274(5292):1531-1534.
87. Hajduk P.J., Sheppard G., Nettesheim D.G., Olejniczak E.T., Shuker S.B., Meadows R.P., et al. Discovery of potent nonpeptide inhibitors of Stromelysin using SAR by NMR. Journal of American chemical society 1997, 119:5818-5827.
88. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature reviews drug discovery 2007, 6(3):211-219.
89. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug discovery today 2004, 9(May):430-431.
90. ActiveSight. ActiveSight fragment library optimized for crystallography. 2007. Available from: <>. http://www.zenobiatherapeutics.com.
91. Wermuth C.G. Selective optimization of side activities: another way for drug discovery. Journal of medicinal chemistry 2004, 47(6):1303-1314.
92. Andersen O.A., Nathubhai A., Dixon M.J., Eggleston I.M., van Aalten D.M. Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin. Chemistry and biology 2008, 15(3):295-301.
93. Willem J., Nissink J.W. Simple size-independent measure of ligand efficiency. Journal of chemical information and modeling 2009, 49(6):1617-1622.
94. Boriack-Sjodin P.A., Zeitlin S., Chen H.H., Crenshaw L., Gross S., Dantanarayana A., et al. Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein science 1998, 7(12):2483-2489.
95. Peltason L., Iyer P., Bajorath J. Rationalizing three-dimensional activity landscapes and the influence of molecular representations on landscape topology and the formation of activity cliffs. Journal of chemical information and modeling 2010, 50(6):1021-1033.
96. Stumpfe D., Bajorath J. Exploring activity cliffs in medicinal chemistry. Journal of medicinal chemistry 2012, 55(7):2932-2942.
97. Verdonk M.L., Rees D.C. Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem 2008, 3(8):1179-1180.
98. Perola E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. Journal of medicinal chemistry. 2010; 53(7): 2986-97.
99. Reynolds C.H., Tounge B.A., Bembenek S.D. Ligand binding efficiency: trends, physical basis, and implications. Journal of medicinal chemistry 2008, 51(8):2432-2438.
100. Reynolds C.H., Holloway K.M. Thermodynamics of ligand binding and efficiency. ACS medicinal chemistry letters 2011, 2:433-437.
101. Garcia-Sosa A.T., Hetenyi C., Maran U. Drug efficiency indices for improvement of molecular docking scoring functions. Journal of computational chemistry 2009, 31(1):174-184.
102. Ferenczy G.G., Keseru G.M. Enthalpic efficiency of ligand binding. Journal of chemical information and modeling 2010, 50(9):1536-1541.
103. Bickerton G.R., Paolini G.V., Besnard J., Muresan S., Hopkins A.L. Quantifying the chemical beauty of drugs. Nature chemistry 2012, 4(2):90-98.
104. Christmann-Franck S., Cravo D., Abad-Zapatero C. Time trajectories in efficiency maps as effective guides for drug discovery efforts. Molecular informatics 2011, 30(2-3):137-144.
105. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 1997, 119(4):681-690.
106. Sweeny D.J., Lynch G., Bidgood A.M., Lew W., Wang K.Y., Cundy K.C. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug metabolism and disposition: the biological fate of chemicals 2000, 28(7):737-741.
107. Abad-Zapatero C., Blasi D. Ligand efficiency indices (LEIs): more than a simple efficiency yardstick. Molecular informatics 2011, 30(2-3):122-132.
108. Abad-Zapatero C., Perisic O., Wass J., Bento P.A., Overington J., Al-Asikani B., Johnson M. Ligand efficiency indices for an effective mapping of chemicobiological space: the concept of an atlas-like representation. Drug discovery today 2010, 15(19-20):804-811.
109. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. Expert opinion in drug discovery 2007, 2(4):469-488.
110. Woltosz W.S. If we designed airplanes like we design drugs. Journal of computer-aided molecular design 2012, 26(1):159-163.
111. Huang N., Shoichet B.K., Irwin J.J. Benchmarking sets for molecular docking. Journal of medicinal chemistry 2006, 49(23):6789-6801.
112. Mysinger M.M., Carchia M., Irwin J.J., Shoichet B.K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. Journal of medicinal chemistry 2012, 55(14):6582-6594.
113. Cortes-Cabrera A., Klett J., Dos Santos H.G., Perona A., Gil-Redondo R., Francis S.M., et al. CRDOCK: an ultrafast multipurpose protein-ligand docking tool. Journal of chemical information and modeling 2012, 52(8):2300-2309.
114. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298(5600):1912-1934.
115. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., et al. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic acids research 2011, 39(Database issue):D1035-D1041.
116. Corey E.J., Czako B., Kurti L. Molecules and Medicine 2007, John Wiley & Sons, Hoboken, NY.
117. Sussman J.L., Harel M., Frolow F., Oefner C., Goldman A., Toker L., et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253(5022):872-879.
118. Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Mathiesen J.M., Sunahara R.K., et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 2012, 485(7398):321-326.
119. Wu H., Wacker D., Mileni M., Katritch V., Han G.W., Vardy E., et al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 2012, 485(7398):327-332.
120. Granier S., Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Weis W.I., et al. Structure of the delta-opioid receptor bound to naltrindole. Nature 2012, 485(7398):400-404.
121. Thompson A.A., Liu W., Chun E., Katritch V., Wu H., Vardy E., et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 2012, 485(7398):395-399.
122. Dortch-Carnes J., Potter D.E. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS drug reviews 2005, 11(2):195-212.
123. Jhoti H., Leach A.R. Structure-based drug discovery 2007, Springer, Dordrecht.
124. Ward R.A., Brassington C., Breeze A.L., Caputo A., Critchlow S., Davies G., et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. Journal of medicinal chemistry 2012, 55(7):3285-3306.
125. Adams M.J., Ford G.C., Koekoek R., Lentz P.J., McPherson A., Rossmann M.G., et al. Structure of lactate dehydrogenase at 2-8Å resolution. Nature 1970, 227(5263):1098-1103.
126. Tanaka D., Tsuda Y., Shiyama T., Nishimura T., Chiyo N., Tominaga Y., et al. A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. Journal of medicinal chemistry 2011.
127. Blasi D., Arsequel G., Valencia G., Nieto J., Planas A., Pinto M., et al. Retrospective mapping of SAR data for TTR protein in chemicobiological space using ligand efficiency indices as a guide to drug discovery strategies. Molecular informatics 2011, 30(2-3):161-167.
128. Mairal T., Nieto J., Pinto M., Almeida M.R., Gales L., Ballesteros A., et al. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PloS one 2009, 4(1):e4124.
129. Masciocchi J., Frau G., Fanton M., Sturlese M., Floris M., Pireddu L., et al. MMsINC: a large-scale chemoinformatics database. Nucleic acids research 2009, 37(Database issue):D284-D290.
130. Wolber G., Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of chemical information and modeling 2005, 45(1):160-169.
131. MOE. Chemical Computing Group Inc., Montreal. Available from: <>. http://www.chemcomp.com.
132. Gonzalez A., Quirante J., Nieto J., Almeida M.R., Saraiva M.J., Planas A., et al. Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and medicinal chemistry letters 2009, 19(17):5270-5273.
133. Adamski-Werner S.L., Palaninathan S.K., Sacchettini J.C., Kelly J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. Journal of medicinal chemistry 2004, 47(2):355-374.
134. Sobel D. Longitude 1995, Walker Publishing Company, Inc., New York.
135. Wilford J.N. The Mapmakers 1982, Vintage Books. A Division of Random House, New York.
136. Sepkowitz K.A. One hundred years of Salvarsan. The New England journal of medicine 2011, 365(4):291-293.
137. Beddell C.R., Goodford P.J., Norrington F.E., Wilkinson S., Wootton R. Compounds designed to fit a site of known structure in human haemoglobin. British journal of pharmacology 1976, 57(2):201-209.
138. Blaney J. A very short history of structure-based design: how did we get here and where do we need to go?. Journal of computer-aided molecular design 2012, 26(1):13-14.
139. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature reviews drug discovery 2007, 6(3):211-219.
140. Jhoti H., Leach A.R. Structure-based drug discovery 2007, Springer, Dordrecht.
141. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug discovery today 2004, 9(May):430-431.